Login to Your Account



Celgene Calls it Quits in GPC Satraplatin Deal

By Donna Young


Friday, August 8, 2008
Celgene Corp. has ended its nearly three-year partnership with embattled German firm GPC Biotech AG on its prostate cancer drug satraplatin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription